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Summary
Objectives: Vagal nerve stimulation (VNS), is an adjunctive therapy approved for use in patients with refractory epilepsy, based on stimula-
tion of the exctracranial part of the vagus nerve. In this study, we provide an analysis of seizure outcomes after VNS implantation for pharma-
cologically resistant epilepsy patients. 
Methods: We reviewed all patients who had VNS implantation in our center from 2005 to June 2013. Patient outcomes were evaluated using 
the VNS-specific outcome scale.
Results: This study consisted of 35 patients (24 males, 11 females; mean age 13.7±8.2 years, range 7 to 40 years). The mean age at VNS im-
plantation was 17.17±8.4 years (range 4 to 35 years). The mean duration of VNS therapy was 26±19.2 months (range 3 to 84 months). The 80% 
of our patients were in the responders, 20% of them were in the nonresponders group.
Conclusion: Vagal nerve stimulation, is an alternative treatment approach. Given the potential for cognitive, behavioural improvement with 
or without improved seizure control, VNS may be considered in the course of treatment of refractory epilepsy.
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Özet
Amaç: Vagal sinir stimülasyonu (VNS), tedaviye dirençli epilepsi hastalarında uygulanan, vagal sinirin ekstrakraniyal bölümünün uyarımına 
dayanan, alternatif bir tedavi yöntemidir. Bu çalışmada, ilaç tedavisine dirençli olup VNS uygulanan hastalar gözden geçirilerek sonuçlar 
değerlendirildi.
Gereç ve Yöntem: 2005 yılından Haziran 2013 tarihine kadar kliniğimizde takip edilen VNS uygulanmış hastalar değerlendirildi. Hastaların 
demografik ve klinik özellikleri ve VNS sonrası nöbet sonlanımı gözden geçirildi.
Bulgular: Vagal sinir stimülasyonu uygulaması yapılan 35 hasta (24 erkek, 11 kadın; ort. yaş 13.7±8.2 yıl; dağılım 7-40 yıl) çalışmaya alındı. 
Ortalama VNS takılma yaşı 17.17 ± 8.4 yıl (dağılım, 4-35 yıl), VNS uygulanması sonrası ortalama takip süresi 26 ± 19.2 ay (dağılım, 3-84 ay) ola-
rak hesaplanmıştır. Hastaların %48.5’i parsiyel nöbetler geçirmektedir. Hastaların %80’i tedaviye yanıtlı, %20’si yanıtsız grupta yer almaktadır.
Sonuç: Vagal Sinir Stimülasyonu, dirençli epilepsi hasta grubunda nöbet sıklığı ve şiddetinin hafifleyebilmesi, kognitif ve davranışsal iyileşme 
sağlayabilmesi ile hastaların yaşam kalitelerini artırabilen alternatif bir tedavi yöntemidir.
Anahtar sözcükler: Dirençli epilepsi; vagal sinir stimülasyonu; VNS.
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ORIGINAL ARTICLE / KLİNİK ÇALIŞMAIntroduction
Epilepsy is a common neurological disease, affecting 0.2-4% 
of the population, that has been known since antiquity.[1] 
Many patients with epilepsy suffer from persistent seizures 
despite appropriate antiepileptic therapy. Uncontrolled sei-
zures are associated with many detrimental effects, includ-
ing cognitive impairment, affective disorders like depres-
sion, reduced quality of life and lower lifetime income and 
higher mortality rates. For drug resistant epilepsy there are, 
non-pharmacological treatment options such as epilepsy 
surgery, the ketogenic diet and vagus nerve stimulation 
therapy (VNS).[2,3]
Vagal Nerve Stimulation is an adjunctive therapy approved 
for use in patients with refractory epilepsy.[4] VNS is used in 
patients with focal seizures with or without secondary gen-
eralization as well as generalized seizures which are refrac-
tory to antiepileptic drugs.[5] The first VNS implant for epi-
lepsy was performed in 1988.[6] Since then more than 60.000 
patients worldwide have been treated with VNS; 30.4% were 
under 18 years and 8.8% were under 12 years age. VNS ther-
apy was approved in Europe in 1994 and by the US Food and 
Drug Administration in 1997 (data on file, Cyberonics, Inc., 
Houston , TX).[7,8] First VNS implantation was applied in 1998 
in Turkey.[9] Currently used implantation conditions were de-
termined by Social Insurance Institution in 2009.[10]
Vagus nerve stimulation therapy is a method based on stim-
ulation of the extra cranial part of the vagus nerve. The neu-
robiological mechanisms of VNS in epilepsy is not clearly 
understood yet. Studies suggest that the vagal stimulation 
may desynchronize activity and decrease abnormal spiking 
patterns on electroencephalography.[11] Putative targets of 
VNS activity have included multiple thalamic and brainstem 
sites proposed to desynchronize thalamocortical circuitry 
involved in seizure propagation.[3,12]
In this study, we provide an analysis of seizure outcomes 
after VNS implantation for pharmacologically resistant epi-
lepsy patients. Clinical response to VNS, patient age, dura-
tion of epilepsy, predominant seizure type, etiology, surgi-
cal complications were investigated as potential prognostic 
indicators of a favorable outcome.
Materials and Methods 
We reviewed all patients who had VNS implantation in our 
center from 2005 to June 2013. Patients with a post-implan-
tation follow-up of at least 3 months and those which had 
a capture of background and follow-up seizure frequency 
were included. Seizure frequency was expressed as a com-
posite of all seizure types experienced by a patient in a given 
month. For each patient gender, onset age of epilepsy, age 
at VNS implantation, ictal semiology, seizure type accord-
ing to the 2010 classification of the International League 
Against Epilepsy,[13,14] underlying etiology (or predisposing 
factors for epilepsy), medications, seizure frequency before 
and after VNS implantation, duration of epilepsy prior to 
VNS, prior intracranial epilepsy surgery were collected from 
the patients’ medical records. Adverse events were recorded 
throughout the study in order to evaluate the safety of VNS.
Patient outcomes were evaluated using the VNS-specific 
outcome scale proposed by McHugh et al. in 2007.[15] In 
this classification, patients are divided into five classes ac-
cording to the percentage of seizure reduction (classes 1-5). 
Patients experiencing a reduction in seizure frequency be-
tween 80-100% were included in class 1, between 50-79% 
in class 2, <50% in class 3, magnet benefit only class 4 and 
patients who had no improvement were added in class 5. 
Then the first three classes are further subdivided into two 
distinct subgroups (A and B) in relation to the improvement 
of duration and severity of ictal and postictal period.[2,15] All 
outcomes (seizure frequency, the number of antiepileptic 
drugs, the quality of life), were compared between the pre 
(6 months before VNS implantation) and post VNS period 
(up to 5 years). The evaluation was based on patients’, par-
ents’ or the caregivers’ observations which included notice-
able changes. Change in quality of life was questioned but 
not qualified, so this information was depending on the 
verbal reports.
Statistical analysis was performed using the Statistical Pack-
age for Social Sciences (SPSS, Chicago, IL, U.S.A.). Descrip-
tive analysis was conducted to summarize patient charac-
teristics. Means were used to describe continuous variables, 
whereas frequency and proportions were used to describe 
categorical variables. For the comparison of VNS effect in 
different age groups (18> and 18≤) a chi-square test was 
used. The relationship between VNS effect and age, age at 
VNS implantation, age at seizure onset, the duration of epi-
lepsy prior to VNS, the duration after VNS implantation was 
evaluated using Mann- Whitney U-test. The value of p<0.05 
was considered statistically significant.
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The mean number of antiepileptic drugs used in our pa-
tient group was 3.4±0.77 for the pre-VNS period while the 
number decreased to 3.08±0.88 in the post-VNS period. Ten 
patients (28.6%) had reduction in the dose or the number 
of antiepileptic drugs after VNS implantation taken over 
time. We have also observed improvement of quality of life 
in some our patients, who had reduction in the frequency 
of seizures, the severity, the duration of the seizures and the 
postictal period.
According to the comparison between well-responders 
(classes 1 and 2) and the others’ (classes 3, 4, and 5) groups; 
Results
This study consisted of 35 patients; 24 male (68.57%) and 
11 females (31.42%). The mean age of patients was 13.7±8.2 
years (7-40 years). The mean age at seizure onset was 5 
years 3±5.1 months for our patient group (newborn-18 
years). Among patients with known underlying etiologies, 
the most common causes included perinatal hypoxia in 7 
(20%), Lennox-Gastaut syndrome in 6 (17.1%), neuronal 
migration disorders in 3 (8.5%), infections like encephalitis 
and meningitis in 3 (8.5%), mesial temporal sclerosis in 2 
(5.7%) patients, West syndrome, Dravet syndrome, Dyke-
Davidoff Masson syndrome, sequelae of ischemia, sequelae 
of intracerebral haemorrhage in 1 (2.9%) patient each. Nine 
patients (25.7%) had unknown etiologies for their epilepsy. 
Focal seizures were the most common type of seizures in 17 
patients (48.5%) followed by generalized seizures in 10 pa-
tients (28.6%). Also 8 patients (22.9%) had both partial and 
generalized seizures simultaneously.
The mean age at VNS implantation was 17.17±8.4 years (4- 
35 years). The mean duration of VNS therapy was 26±19.2 
months (3- 84 months). The seizure outcomes at last follow-
up visit according to the McHugh classification is shown in 
the Tables 1, 2 and Figure 1.
Table 1.  The seizure outcomes according to the McHugh classification
  Class 1a  Class 1b  Class 2a  Class 2b  Class 3a  Class 3b  Class 4  Class 5
Number of patients (n)  0  2  7  7  2  11  1  5
Percentage (%)  0  5.7  20  20  5.7  31.4  2.9  14.3
Table 2.  Distribution of patients data according to the McHugh classification
  Class 1  Class 2  Class 3  Class 4  Class 5
Number of patients = n (%)  2 (5.7)  14 (40)  13 (37.1)  1 (2.9)  5 (14.3)
Gender  1F, 2M  7F, 7M  2 F, 11 M  1 M  1 F, 4 M
Etiology  1 E, 1 MTS  1 NMD, 3PH, 3U,   3 PH, 1 NMD, 5 U,   1 PH  1 NMD, 1 LGS,  
    5LGS, 1DS, 1E  1 MTS, 1 MNG,     1 WS, 1PH, 1U
      1 ICH, 1 DDMS
Seizure type   2 FC  6 FC, 6 G, 2 FC&G  8 FC, 2 G, 3 FC&G,  1 FC  3 FC&G, 1 G
Reduction of antiepileptic  1 yes  6 yes  2 yes  1 yes  5 no
drugs  1 no  8 no  11 no
F: Female; M: Male; FC: Focal; G: Generalized; FC&G: Both focal and generalized seizure types occurring in the same patient; NMD: Neuronal migration 
disorders; PH: Perinatal hypoxia; U: Unknown; LGS: Lennox-Gastaut syndrome; DS: Dravet syndrome; E: Encephalitis; MTS: Mesial temporal sclerosis; 
WS: West syndrome; ICH: Intracerebral hemorrhage; DDMS: Dyke-Davidoff Masson syndrome; MNG: Meningitis.
Figure 1. Distribution of percentages of classes according to 
the McHugh classification.
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there was no significant difference for recent age, age at 
VNS implantation, age at seizure onset, the duration of epi-
lepsy prior to VNS, the duration after VNS implantation (p 
values were as follows: p=0.909; p=0.683; p=0.961; p=0.317; 
p=0.523). Also, there was no significant difference between 
well-responders and others group for patients under the 
age of 18 and above 18 years at VNS implantation (p=0.922). 
The number of patients according to this groups were sum-
marized in Table 3.
Adverse events considered to be specific for VNS was re-
ported in 9 patients (25.7%). Intermittent couch occurred in 
8.5%, localized neck pain and/or paresthesias in 11.4%, in-
termittent hoarseness in 5.8% of them. Twenty six patients 
(74.3%) did not have side effects.
Three patients (8.5%) had underwent failed epilepsy sur-
gery procedures before implantation of VNS. One patient 
had temporal lobectomy, one had selective amigdalohip-
pocampectomy and the other one had fronto- insular resec-
tion, all without success.
Discussion
Vagal nerve stimulation, is an alternative treatment ap-
proach for the epilepsy patients refractory to antiepileptic 
medications. It is getting a widespread usage because it 
does not have interactions with antiepileptic drugs. Based 
on clinical observations, effects of treatment varies and VNS 
decreases the frequency and severity of seizure.[7,8] Here, in 
this study we investigated the effects of VNS treatment in 
patients with phamacoresistant epilepsy.
Uncontrolled seizures are associated with many other con-
sequences including cognitive impairment, reduced life-
time income, higher risk of accidental injuries and higher 
rates of depression.[16] Vagal Nerve Stimulation, not only 
decreases the frequency of seizures but may also decrease 
the severity, duration of the seizures and also the postictal 
period. That may explain why we have observed improve-
ment of quality of life in our patients.
According to the McHugh classification, patients experienc-
ing a >50% seizure frequency reduction in respect to the 
baseline were considered as well-responders (classes 1 and 
2), <50% seizure frequency reduction were considered as 
less responsive (classes 3 and 4) and nonresponders (class 5). 
In our patient population nearly 80% of them were respond-
ers (well and less responsive totally=classes 1, 2, 3 and 4) 
and almost 46% of them were in the well-responders (class 
1 and 2) group. In the previous reports the >50% seizure 
control rate was notified as differing between range 23.4% 
and 63.8%.[17,18] Although most of the patients in our sample 
were in responders group, still 20% were nonresponders.
Various studies compared clinical response to VNS therapy 
in children and adults. Bao et al. have noticed better prog-
nosis in adults than children.[2] According to the data ob-
tained from the VNS patient outcome report provided by 
the manufacturer of the device, clinical response to VNS 
therapy was better, in patients under the age 18 when com-
pared the adults over 18 years.[19] In our study there was no 
significant difference between children and adults for this 
statement (p>0.05).
In our study, 10 patients (28.6%) had reduction in the dose 
or the number of antiepileptic drugs after VNS implanta-
tion. A slight decrease of antiepileptic drugs was reported 
in another study by Majkowska-Zwolińska et al.[7] whereas 
no significant reduction after VNS implantation over one 
year follow up was stated by Elliott et al.[20] The reduction in 
usage of antiepileptic drugs is very important from clinical 
point of view, since chronic use of these drugs may cause 
several side effects which contributes the impairment of 
quality of life in these patients.
Side effects observed due to VNS in our patients were 
Table 3.  The seizure outcomes according to the VNS implantation age
    Well-responders  Others
  (Classes 1 and 2)  (Classes 3, 4 and 5)
  n %  n %
Number of patients <18 years (n)  9  56.2  11  57.9
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hoarseness, throat pain and cough, as formerly described 
in the literature.[17,21] Other common adverse events of VNS, 
that were not present in our group of patients include 
bleeding and infection from the surgery, dyspnea, transi-
tory hypotension, ventricular asystole, dyspnea, dyspepsia, 
dysphagia, vomiting, pharyngitis, headache and psychosis. 
Nearly two thirds of 57 patients in the study of Majkowska-
Zwolińska et al.[7] experienced no adverse events specifi-
cally related to VNS. So we agree that this treatment is a safe 
option with minor side effects and injuries. 
Main limitation of similar VNS studies is also valid for ours. 
First, the information before VNS implantation is obtained 
retrospectively therefore the seizure frequency and severity 
were defined with crude measures by patients or caregivers 
and this is subject to error. QoL scales were also not applied 
to the patients due to the difficulty of communication in 
many of them because of their low IQ, at this point a scale 
is needed to be developed for parents to quantify their ob-
servation. Furthermore, we were not able to identify altera-
tions in seizure frequency for specific seizure subtypes in 
our results as many of the patients suffer from several types 
of seizures occurring several times a day which makes it dif-
ficult for the caregivers to record them correctly.
Vagal nerve stimulation is safe and can be an effective al-
ternative option for adult and pediatric patients with medi-
cally refractory epilepsy. It seems that frequent changes in 
antiepileptic drug regimens and VNS together may play 
synergistic roles in seizure control. Other factors affecting 
the prognosis of VNS treatment remains unclear and we ex-
pect to acquire more information with increasing number 
of cases. Given the potential for cognitive, behavioural im-
provement with or without improved seizure control, VNS 
may be considered in the course of treatment of refractory 
epilepsy.
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